Prometheus Biosciences, Inc. (RXDX) Covered Calls

Prometheus Biosciences, Inc. covered calls Ignyta Inc is a precision oncology biotechnology company. It is dedicated to discovering or acquiring, then developing and commercializing, precisely targeted new drugs for cancer patients whose tumors harbor specific molecular alterations.

You can sell covered calls on Prometheus Biosciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RXDX (prices last updated Thu 4:16 PM ET):

Prometheus Biosciences, Inc. (RXDX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
114.47 -4.64 110.01 120.00 351K - 5.0
Covered Calls For Prometheus Biosciences, Inc. (RXDX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Feb 17 115 5.90 114.10 0.8% 12.7%
Mar 17 115 10.20 109.80 4.7% 33.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Ignyta, Inc. is a precision oncology biotechnology company. It engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. Currently, the company's development plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. Ignyta was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.